ABOUT CIALIS

In October 2007, the FDA declared which the labeling for all PDE5 inhibitors, such as tadalafil, needs a additional distinguished warning of the potential risk of sudden hearing reduction as the results of write-up-marketing and advertising reports of temporary deafness connected to utilization of PDE5 inhibitors.[19]"This technological innovation